Balloon Valvuloplasty — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Balloon valvuloplasty is a minimally invasive catheter-based procedure to widen narrowed (stenotic) heart valves, restoring normal blood flow without open-heart surgery. A deflated balloon catheter is threaded through a blood vessel into the heart, positioned precisely across the stenotic valve, and inflated to separate fused valve leaflets and increase the valve opening area. Three cardiac valves can be treated: the mitral valve (most commonly, for rheumatic mitral stenosis), the pulmonary valve (for congenital pulmonary stenosis), and the aortic valve (as a palliative or bridging procedure in selected high-risk cases). The procedure was first described by Inoue in 1984 for mitral stenosis and remains the gold-standard catheter-based treatment for suitable rheumatic mitral stenosis worldwide, particularly in countries where rheumatic fever is prevalent. Careful patient selection based on valve morphology scoring (Wilkins score) determines the likelihood of a good outcome. Balloon valvuloplasty is a minimally invasive catheter-based procedure to widen narrowed (stenotic) heart valves, restoring normal blood flow without open-heart surgery. A deflated balloon catheter is advanced across the stenotic valve and inflated to fracture fused valve leaflets or commissures, increasing valve orifice area. It is most commonly performed for mitral stenosis (percutaneous mitral balloon valvuloplasty — PMBV, or the Inoue balloon technique), pulmonary stenosis (the most successful application with excellent long-term outcomes), and occasionally for calcific aortic stenosis when transcatheter aortic valve replacement (TAVR) is planned as a bridge procedure. Balloon aortic valvuloplasty (BAV) for calcific aortic stenosis provides only temporary benefit (6–12 months) and has largely been replaced by TAVR. The procedure is performed by interventional cardiologists in a cardiac catheterisation laboratory and was first described for mitral stenosis by Kanji Inoue in 1982.

Percutaneous mitral balloon valvuloplasty (PMBV) is indicated for symptomatic mitral stenosis (NYHA Class II–IV) with favourable valve morphology (Wilkins score of 8 or less — pliable, non-calcified, non-thickened leaflets with minimal subvalvular disease), mitral valve area below 1.5 cm², absence of significant mitral regurgitation, and no left atrial thrombus. It is also indicated for asymptomatic severe mitral stenosis with new-onset atrial fibrillation or pulmonary hypertension (systolic >50 mmHg at rest). Balloon pulmonary valvuloplasty is the treatment of choice for symptomatic congenital pulmonary stenosis in children and adults, with peak gradient above 40 mmHg by Doppler. Balloon aortic valvuloplasty is reserved for patients with severe symptomatic aortic stenosis who are too high-risk for surgical or transcatheter valve replacement (TAVI) — it is palliative because restenosis occurs within 6–12 months in 50% of patients. Contraindications to PMBV include moderate-to-severe mitral regurgitation, left atrial thrombus, and heavily calcified or immobile valves.

For percutaneous mitral balloon valvuloplasty, vascular access is obtained via the right femoral vein under local anaesthesia and sedation. A transseptal puncture is made through the interatrial septum using a Brockenbrough needle under fluoroscopic and echocardiographic guidance, creating access to the left atrium. The Inoue balloon catheter — a specially designed hourglass-shaped balloon — is advanced into the left ventricle across the stenotic mitral valve. The distal portion of the balloon inflates first and anchors in the ventricle; the balloon is then pulled back to straddle the mitral valve, and full inflation separates the fused commissures. Balloon size is calculated from patient height. The result is assessed immediately by echocardiography; further inflations can be performed stepwise if the initial result is insufficient and no significant regurgitation has developed. For pulmonary valvuloplasty, femoral venous access is used directly; a large Tyshak balloon is inflated across the pulmonary valve. The procedure takes 1–3 hours. For percutaneous mitral balloon valvuloplasty (PMBV), vascular access is obtained via the right femoral vein under local anaesthesia and sedation. A transseptal puncture is made through the interatrial septum using a Brockenbrough needle under fluoroscopic and echocardiographic guidance. The Inoue balloon catheter is then advanced across the mitral valve into the left ventricle. The balloon is inflated sequentially — distal portion first to anchor it, then proximal portion — splitting the fused commissures and enlarging the mitral valve orifice. Post-dilation echocardiography immediately assesses valve area, transmitral gradient, and presence of new mitral regurgitation before any further inflation. Pulmonary balloon valvuloplasty uses similar technique via the femoral vein, with the balloon advanced across the pulmonary valve. Post-procedure, the catheters and sheath are removed and haemostasis achieved. Total procedure time is 60–120 minutes.

Percutaneous mitral balloon valvuloplasty doubles the mitral valve area (from approximately 1.0 to 2.0 cm²) in over 90% of appropriately selected patients with good valve morphology. Symptomatic improvement — reduction in dyspnoea, exercise intolerance, and pulmonary congestion — is immediate and dramatic for most patients. In rheumatic mitral stenosis, event-free survival (freedom from death, mitral valve surgery, or repeat valvuloplasty) is 50–70% at 10–15 years in patients with low Wilkins scores, making it a genuinely durable treatment. Pulmonary valvuloplasty achieves gradient reduction below 30 mmHg in 90%+ of patients, with excellent long-term results — recurrence requiring repeat intervention occurs in fewer than 10% at 10 years. Patients avoid open-heart surgery, cardiopulmonary bypass, prolonged hospitalisation, and the complications of surgical commissurotomy. For rheumatic populations in developing countries, PMBV offers a lifesaving intervention that restores functional capacity and avoids the cost and risk of surgical valve replacement.

Serious but rare complications at experienced centres affect fewer than 2–3% of patients. The principal procedural risk is development of significant mitral regurgitation (MR) requiring emergency surgical intervention in approximately 1–3% of cases — this occurs when one commissure splits unevenly, causing leaflet prolapse. Stroke or systemic embolism occurs in approximately 0.5–1% due to thrombus displacement or catheter-related embolisation; peri-procedural anticoagulation and exclusion of left atrial thrombus by transoesophageal echocardiography before the procedure mitigate this risk. Cardiac perforation leading to tamponade occurs in approximately 0.5–1% — related to the transseptal puncture — and requires urgent pericardiocentesis or surgical repair. Haematoma at the femoral access site is the most common minor complication. Persistent interatrial septal defect following transseptal puncture is usually small and haemodynamically insignificant. Overall procedural mortality in large case series from experienced centres is less than 0.5%.

Hospital stay is typically 1–3 days after PMBV. The femoral venous access site is compressed for 4–6 hours. Patients are monitored with repeat echocardiography before discharge to confirm valve area, absence of significant regurgitation, and resolution of pulmonary hypertension. Anticoagulation with warfarin or DOAC is prescribed for patients with atrial fibrillation. Patients with sinus rhythm and successful PMBV may have anticoagulation stopped after 4–6 weeks once left atrial function recovers. Physical activity resumes within 1 week; return to work within 1–2 weeks. Regular echocardiography follow-up is performed at 1 month, 6 months, then annually. Restenosis (valve area falling below 1.5 cm²) is monitored — when it occurs, repeat PMBV is feasible in suitable patients, or surgical mitral valve repair or replacement is arranged. Antibiotic prophylaxis against rheumatic fever recurrence with monthly benzathine penicillin injections is recommended for younger patients living in endemic areas.